News
CAMBRIDGE, Mass., Sept. 05, 2024 -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback